Cannabis for migraine treatment: The once and future prescription? An historical and scientific review

Pain

Volumn 76, Issue 1-2, 1998, Pages 3-8

  Russo, Ethan ^a  

^a Department of Neurology   (United States)

Author keywords

Cannabis; Dronabinol; Ethnobotany; Headache; Marijuana; Migraine

Indexed keywords

CANNABIS; DRONABINOL; SUMATRIPTAN; TETRAHYDROCANNABINOL;

DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INDICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG SCREENING; MIGRAINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0031746092     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(98)00033-5     Document Type: Article

References (52)

1. Agurell S., Halldin M., Lindgren J.-E., Ohlsson A., Widman M., Gillespie H., Hollister L. Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38:1986;21-43.
2. AJPH Access to therapeutic marijuana/cannabis. Am. J. Public Health. 86:1996;441-442.
3. Brunner T.F. Marijuana in ancient Greece and Rome? The literary evidence. J. Psychedel. Drugs. 9:1977;221-225.
4. Camp W.H. The antiquity of hemp as an economic plant. J. N. Y. Bot. Gard. 37:1936;110-114.
5. Chait L.D., Zacny J.P. Reinforcing and subjective effects of oral delta-9-THC and smoked marijuana in humans. Psychopharmacology. 107:1992;255-262.
6. Chiang C.N., Barnett G. Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin. Pharm. Ther. 36:1984;234-238.
7. Chopra I.C., Chopra R.W. The use of cannabis drugs in India. Bull. Narcotics. 9:1957;4-29.
8. Co B.T., Goodwin D.W., Gado M., Mikhael M., Hill S.Y. Absence of cerebral atrophy in chronic cannabis users by computerized transaxial tomography. J. Am. Med. Assoc. 237:1977;1229-1230.
9. Cohen S. The 94-day cannabis study. Ann. N. Y. Acad. Sci. 282:1976;211-220.
10. Comitas L. Cannabis and work in Jamaica: a refutation of the amotivational syndrome. Ann. N. Y. Acad. Sci. 282:1976;211-220.
11. Darmsteter, J. (trans.), The Zend-Avesta, Part I, The Vendîdâd, Oxford, London, 1895, 389 pp.
12. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
13. Dwarakanath C. Use of opium and cannabis in the traditional systems of medicine in India. Bull. Narcotics. 17:1965;15-19.
14. El-Mallakh R.F. Marijuana and migraine. Headache. 27:1987;442-443.
15. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73:1995;907-910.
16. Ferrari M.D., Saxena P.R. 5-HT1 receptors in migraine pathophysiology and treatment. Eur. J. Neurol. 2:1995;5-21.
17. Fishbein M. Migraine associated with menstruation. J. Am. Med. Assoc. 237:1942;326.
18. Fisher M.A., Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 48:1997;1156-1160.
19. Foltin R.W., Fischman M.W., Byrne M.F. Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 11:1988;1-14.
20. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
21. Gieringer D. Waterpipe study. Bull. Multidisc. Assoc. Psychedel. Stud. 6:1996;59-63.
22. 3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann. Neurol. 29:1991;91-94.
23. Grinspoon, L. and Bakalar, J.B., Marihuana: The Forbidden Medicine, Yale University, New Haven, CT, 1993, 184 pp.
24. Grinspoon L., Bakalar J.B. Marihuana as medicine: a plea for reconsideration. J. Am. Med. Assoc. 273:1995;1875.
25. Hall, W., Solowij, N. and Lemon, J., The Health and Psychological Consequences of Cannabis Use, National Drug Strategy Monograph Series No. 25, National Drug and Alcohol Research Centre, Australia, 1995.
26. Herkenham, M.A., Localization of cannabinoid receptors in brain: relationship to motor and reward systems. In: S.G. Koreman and J.D. Barchas (eds.), Biological Basis of Substance Abuse, Oxford University Press, London, 1993, pp. 187-200.
27. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
28. Kuehnle J., Mendelson J.H., Davis K.R., New P.F.J. Computed tomographic examination of heavy marihuana smokers. J. Am. Med. Assoc. 237:1977;1231-1232.
29. Li H.-L. An archaeological and historical account of cannabis in China. Econ. Bot. 28:1974;437-448.
30. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
31. Linet M.S., Stewart W.F., Celentano D.D. An epidemiological study of headache among adolescents and young adults. J. Am. Med. Assoc. 261:1989;2211-2216.
32. Lipton R.B., Stewart W.F. Migraine in the United States: epidemiology and health care use. Neurology. 43(suppl.):1993;6-10.
33. Martin B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:1986;45-74.
34. Mason A.P., McBay A.J. Cannabis: pharmacology and interpretation of effects. J. Forens. Sci. 30:1985;615-631.
35. Mathew N.T. Serotonin 1D (5-HT 1D) agonists and other agents in acute migraine. Neurol. Clinics. 15:1997;61-83.
36. Mikuriya, T.H. (Ed.), Marijuana: Medical Papers 1839-1972, Medi-Comp Press, Oakland, CA, 1973, 465 pp.
37. Milstein S.L., MacCannell K., Karr G., Clark S. Marijuana-produced changes in pain tolerance: experienced and non-experienced subjects. Int. Neuropsychiatr. 10:1975;177-182.
38. Noyes R., Baram D.A. Cannabis analgesia. Comp. Psychiatr. 15:1974;531-535.
39. Noyes, R., Brunk, F., Baram, D.A. and Canter, A., Analgesic effect of delta-9-tetrahydrocannabinol, J. Clin. Pharmacol., 15 (1975a) 134-143.
40. Noyes, R., Brunk, F., Avery, D.H. and Canter, A., The analgesic properties of delta-9-tetrahydrocannabinol and codeine, Clin. Pharmacol. Ther., 18 (1975b) 84-89.
41. Osler, W. and McCrae, T., The Principles and Practice of Medicine, Appleton, New York, 1915, 1225 pp.
42. Peroutka S.J. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol. Clinics. 8:1990;829-839.
43. Ratnam E.V. Cannabis indica, J. Brit. Med Assoc. Ceylon Branch. 13:1916;30-34.
44. Schultes, R.E., Man and marijuana, Nat. Hist., 82 (1973) 59-63, 80, 82.
45. Schultes R.E., Klein W.M., Plowman T., Lockwood T.E. Cannabis: an example of taxonomic neglect. Bot. Mus. Leafl. Harvard Univ. 23:1974;337-367.
46. Sidney S., Beck J.E., Tekawa I.S., Quesenberry C.P., Friedman G.D. Marijuana use and mortalilty. Am. J. Public Health. 87:1997;585-590.
47. Smith R. Editorial: the war on drugs. Br. Med. J. 311:1995;23-30.
48. Stewart W.F., Lipton R.B., Celantano D.D. Prevalence of migraine headache in the United States. J. Am. Med. Assoc. 267:1992;64-69.
49. Volfe Z., Dvilansky A., Nathan I. Cannabinoids block release of serotonin from platelets by plasma from migraine patients. Int. J. Clin. Pharm. Res. 4:1985;243-246.
50. Voth E.A., Schwartz R.H. Medical applications of delta-9-tetrahydrocannabinol and marijuana. Ann. Intern. Med. 126:1997;791-798.
51. Walton, R.P., Marihuana: America's New Drug Problem: A Sociologic Question with its Basic Explanation Dependent on Biologic and Medical Principles, Lippincott, Philadelphia, PA, 1938, 223 pp.
52. Young, F.L., In the Matter of Marijuana Rescheduling Petition, Department of Justice, Drug Enforcement Administration. Docket 86-22, Drug Enforcement Administration, Washington, DC, September 6, 1988.